We are analyzing https://link.springer.com/article/10.1007/s10555-025-10261-7.

Title:
CAR T-cells for acute leukemias in children: current status, challenges, and future directions | Cancer and Metastasis Reviews
Description:
CAR T-cells therapy is seen as one of the most promising immunotherapies for leukemias, since targeting CD19 has revolutionized the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) in children, adolescents, and young adults. Early phase clinical trials have shown a very high initial response rate confirmed by follow up and real-world studies. However, almost half of patients relapse with the available commercial product currently suggesting the need of a consolidative treatment after CAR T-cell infusion in well-defined cases, according to several pre- and post-CAR clinical and biological factors. This finding highlights that numerous challenges exist before the extension of CAR T-cell indications (first relapse and high-risk first line) in the field of B-ALL: to enhance persistence of CAR T-cells to avoid CD19-positive relapse and to avoid CD19-negative relapse by reducing tumor burden pre-CAR-T infusion and/or by multitargeting. Promising approaches with exciting early clinical data are emerging in the field of T-cell ALL. The use of CAR T-cells for acute myeloid leukemias remains challenging due to the lack of leukemia-specific antigens and to the immunosuppressive microenvironment.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Insurance
Science
Education

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We're unsure if the website is profiting.

While many websites aim to make money, others are created to share knowledge or showcase creativity. People build websites for various reasons. This could be one of them. Link.springer.com might be earning cash quietly, but we haven't detected the monetization method.

Keywords {🔍}

article, pubmed, google, scholar, car, acute, therapy, leukemia, tcell, cells, central, blood, lymphoblastic, cell, antigen, children, chimeric, journal, cart, receptor, nature, clinical, cancer, young, phase, pediatric, bcell, adults, patients, relapsed, trial, relapse, refractory, medicine, relapsedrefractory, ball, leukaemia, oncology, tcells, treatment, targeting, tisagenlecleucel, theraphy, research, myeloid, outcomes, advances, paris, data, dourthe,

Topics {✒️}

necker enfants-malades hospital single-cell antigen-specific landscape cd19-dim b-lymphoblastic leukemia month download article/chapter cd19-car t-cell therapy relapsed/refractory t-cell malignancies donor-derived cd123-targeted car shelf’ fratricide-resistant car fratricide-resistant cd7-car b-cell lymphoblastic leukemia chimeric antigen receptor car t-cell indications aggressive t-cell malignancies car t-cell therapy cd33-car nk-92 cells prevent antigen-negative relapse car t-cell activity decade-long leukaemia remissions car t-cell infusion acute lymphoblastic leukaemia cd19/cd22 bispecific car low-affinity cd19 car cd5 car t-cells avoid cd19-negative relapse acute myeloid leukemia cd19 car t-cells acute lymphoblastic leukemia leukemia-free survival advantage cd19+ relapsed/refractory malignancies pediatric relapsed/refractory bcp single-cell profiling long-term follow anti-cd7 car avoid cd19-positive relapse accepted manuscript version t-cell therapy t-cell malignancy crispr-engineered car19 universal t-cell malignancies cd19-directed car cd7-specific car anti-tumor activity cd19/cd22 targeting t-cell potency demonstrates durable efficacy unicar-t-cd123 andré baruchel car nk cells car nk-92 cells cd38-directed car

Schema {🗺️}

WebPage:
      mainEntity:
         headline:CAR T-cells for acute leukemias in children: current status, challenges, and future directions
         description:CAR T-cells therapy is seen as one of the most promising immunotherapies for leukemias, since targeting CD19 has revolutionized the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) in children, adolescents, and young adults. Early phase clinical trials have shown a very high initial response rate confirmed by follow up and real-world studies. However, almost half of patients relapse with the available commercial product currently suggesting the need of a consolidative treatment after CAR T-cell infusion in well-defined cases, according to several pre- and post-CAR clinical and biological factors. This finding highlights that numerous challenges exist before the extension of CAR T-cell indications (first relapse and high-risk first line) in the field of B-ALL: to enhance persistence of CAR T-cells to avoid CD19-positive relapse and to avoid CD19-negative relapse by reducing tumor burden pre-CAR-T infusion and/or by multitargeting. Promising approaches with exciting early clinical data are emerging in the field of T-cell ALL. The use of CAR T-cells for acute myeloid leukemias remains challenging due to the lack of leukemia-specific antigens and to the immunosuppressive microenvironment.
         datePublished:2025-04-23T00:00:00Z
         dateModified:2025-04-23T00:00:00Z
         pageStart:1
         pageEnd:19
         sameAs:https://doi.org/10.1007/s10555-025-10261-7
         keywords:
            Acute lymphoblastic leukemia
            Acute myeloid leukemia
            Immunotherapy
            CAR T-cells
            Children
            Cancer Research
            Oncology
            Biomedicine
            general
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10555-025-10261-7/MediaObjects/10555_2025_10261_Fig1_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10555-025-10261-7/MediaObjects/10555_2025_10261_Fig2_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10555-025-10261-7/MediaObjects/10555_2025_10261_Fig3_HTML.png
         isPartOf:
            name:Cancer and Metastasis Reviews
            issn:
               1573-7233
            volumeNumber:44
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer US
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Marie Emilie Dourthe
               affiliation:
                     name:Robert Debré University Hospital, Assistance Publique-Hôpitaux de Paris (APHP) and Université Paris Cité
                     address:
                        name:Pediatric Hematology-Immunology Department, Robert Debré University Hospital, Assistance Publique-Hôpitaux de Paris (APHP) and Université Paris Cité, Paris, France
                        type:PostalAddress
                     type:Organization
                     name:Institut National de La Santé Et de La Recherche Médicale (Inserm) U1151, Assistance Publique-Hôpitaux de Paris (APHP), Necker Enfants-Malades Hospital, Université Paris Cité
                     address:
                        name:Institut Necker-Enfants Malades (INEM), Institut National de La Santé Et de La Recherche Médicale (Inserm) U1151, Assistance Publique-Hôpitaux de Paris (APHP), Necker Enfants-Malades Hospital, Université Paris Cité, Paris, France
                        type:PostalAddress
                     type:Organization
               type:Person
               name:André Baruchel
               affiliation:
                     name:Robert Debré University Hospital, Assistance Publique-Hôpitaux de Paris (APHP) and Université Paris Cité
                     address:
                        name:Pediatric Hematology-Immunology Department, Robert Debré University Hospital, Assistance Publique-Hôpitaux de Paris (APHP) and Université Paris Cité, Paris, France
                        type:PostalAddress
                     type:Organization
                     name:Institut de Recherche Saint-Louis, ECSTRRA team, Université Paris Cité
                     address:
                        name:Institut de Recherche Saint-Louis, ECSTRRA team, Université Paris Cité, Paris, France
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:CAR T-cells for acute leukemias in children: current status, challenges, and future directions
      description:CAR T-cells therapy is seen as one of the most promising immunotherapies for leukemias, since targeting CD19 has revolutionized the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) in children, adolescents, and young adults. Early phase clinical trials have shown a very high initial response rate confirmed by follow up and real-world studies. However, almost half of patients relapse with the available commercial product currently suggesting the need of a consolidative treatment after CAR T-cell infusion in well-defined cases, according to several pre- and post-CAR clinical and biological factors. This finding highlights that numerous challenges exist before the extension of CAR T-cell indications (first relapse and high-risk first line) in the field of B-ALL: to enhance persistence of CAR T-cells to avoid CD19-positive relapse and to avoid CD19-negative relapse by reducing tumor burden pre-CAR-T infusion and/or by multitargeting. Promising approaches with exciting early clinical data are emerging in the field of T-cell ALL. The use of CAR T-cells for acute myeloid leukemias remains challenging due to the lack of leukemia-specific antigens and to the immunosuppressive microenvironment.
      datePublished:2025-04-23T00:00:00Z
      dateModified:2025-04-23T00:00:00Z
      pageStart:1
      pageEnd:19
      sameAs:https://doi.org/10.1007/s10555-025-10261-7
      keywords:
         Acute lymphoblastic leukemia
         Acute myeloid leukemia
         Immunotherapy
         CAR T-cells
         Children
         Cancer Research
         Oncology
         Biomedicine
         general
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10555-025-10261-7/MediaObjects/10555_2025_10261_Fig1_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10555-025-10261-7/MediaObjects/10555_2025_10261_Fig2_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10555-025-10261-7/MediaObjects/10555_2025_10261_Fig3_HTML.png
      isPartOf:
         name:Cancer and Metastasis Reviews
         issn:
            1573-7233
         volumeNumber:44
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Marie Emilie Dourthe
            affiliation:
                  name:Robert Debré University Hospital, Assistance Publique-Hôpitaux de Paris (APHP) and Université Paris Cité
                  address:
                     name:Pediatric Hematology-Immunology Department, Robert Debré University Hospital, Assistance Publique-Hôpitaux de Paris (APHP) and Université Paris Cité, Paris, France
                     type:PostalAddress
                  type:Organization
                  name:Institut National de La Santé Et de La Recherche Médicale (Inserm) U1151, Assistance Publique-Hôpitaux de Paris (APHP), Necker Enfants-Malades Hospital, Université Paris Cité
                  address:
                     name:Institut Necker-Enfants Malades (INEM), Institut National de La Santé Et de La Recherche Médicale (Inserm) U1151, Assistance Publique-Hôpitaux de Paris (APHP), Necker Enfants-Malades Hospital, Université Paris Cité, Paris, France
                     type:PostalAddress
                  type:Organization
            type:Person
            name:André Baruchel
            affiliation:
                  name:Robert Debré University Hospital, Assistance Publique-Hôpitaux de Paris (APHP) and Université Paris Cité
                  address:
                     name:Pediatric Hematology-Immunology Department, Robert Debré University Hospital, Assistance Publique-Hôpitaux de Paris (APHP) and Université Paris Cité, Paris, France
                     type:PostalAddress
                  type:Organization
                  name:Institut de Recherche Saint-Louis, ECSTRRA team, Université Paris Cité
                  address:
                     name:Institut de Recherche Saint-Louis, ECSTRRA team, Université Paris Cité, Paris, France
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Cancer and Metastasis Reviews
      issn:
         1573-7233
      volumeNumber:44
Organization:
      name:Springer US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Robert Debré University Hospital, Assistance Publique-Hôpitaux de Paris (APHP) and Université Paris Cité
      address:
         name:Pediatric Hematology-Immunology Department, Robert Debré University Hospital, Assistance Publique-Hôpitaux de Paris (APHP) and Université Paris Cité, Paris, France
         type:PostalAddress
      name:Institut National de La Santé Et de La Recherche Médicale (Inserm) U1151, Assistance Publique-Hôpitaux de Paris (APHP), Necker Enfants-Malades Hospital, Université Paris Cité
      address:
         name:Institut Necker-Enfants Malades (INEM), Institut National de La Santé Et de La Recherche Médicale (Inserm) U1151, Assistance Publique-Hôpitaux de Paris (APHP), Necker Enfants-Malades Hospital, Université Paris Cité, Paris, France
         type:PostalAddress
      name:Robert Debré University Hospital, Assistance Publique-Hôpitaux de Paris (APHP) and Université Paris Cité
      address:
         name:Pediatric Hematology-Immunology Department, Robert Debré University Hospital, Assistance Publique-Hôpitaux de Paris (APHP) and Université Paris Cité, Paris, France
         type:PostalAddress
      name:Institut de Recherche Saint-Louis, ECSTRRA team, Université Paris Cité
      address:
         name:Institut de Recherche Saint-Louis, ECSTRRA team, Université Paris Cité, Paris, France
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Marie Emilie Dourthe
      affiliation:
            name:Robert Debré University Hospital, Assistance Publique-Hôpitaux de Paris (APHP) and Université Paris Cité
            address:
               name:Pediatric Hematology-Immunology Department, Robert Debré University Hospital, Assistance Publique-Hôpitaux de Paris (APHP) and Université Paris Cité, Paris, France
               type:PostalAddress
            type:Organization
            name:Institut National de La Santé Et de La Recherche Médicale (Inserm) U1151, Assistance Publique-Hôpitaux de Paris (APHP), Necker Enfants-Malades Hospital, Université Paris Cité
            address:
               name:Institut Necker-Enfants Malades (INEM), Institut National de La Santé Et de La Recherche Médicale (Inserm) U1151, Assistance Publique-Hôpitaux de Paris (APHP), Necker Enfants-Malades Hospital, Université Paris Cité, Paris, France
               type:PostalAddress
            type:Organization
      name:André Baruchel
      affiliation:
            name:Robert Debré University Hospital, Assistance Publique-Hôpitaux de Paris (APHP) and Université Paris Cité
            address:
               name:Pediatric Hematology-Immunology Department, Robert Debré University Hospital, Assistance Publique-Hôpitaux de Paris (APHP) and Université Paris Cité, Paris, France
               type:PostalAddress
            type:Organization
            name:Institut de Recherche Saint-Louis, ECSTRRA team, Université Paris Cité
            address:
               name:Institut de Recherche Saint-Louis, ECSTRRA team, Université Paris Cité, Paris, France
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Pediatric Hematology-Immunology Department, Robert Debré University Hospital, Assistance Publique-Hôpitaux de Paris (APHP) and Université Paris Cité, Paris, France
      name:Institut Necker-Enfants Malades (INEM), Institut National de La Santé Et de La Recherche Médicale (Inserm) U1151, Assistance Publique-Hôpitaux de Paris (APHP), Necker Enfants-Malades Hospital, Université Paris Cité, Paris, France
      name:Pediatric Hematology-Immunology Department, Robert Debré University Hospital, Assistance Publique-Hôpitaux de Paris (APHP) and Université Paris Cité, Paris, France
      name:Institut de Recherche Saint-Louis, ECSTRRA team, Université Paris Cité, Paris, France
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(335)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.15s.

LINK . SPRINGER . COM {}